--- title: "The First Approved Brain–Computer Implant Is Now Helping Paralyzed Patients in China" date: 2026-10-29 category: AI in Action site: NeuroAI canonical: https://neuroai.site/a/na-app-neo-bci-clinic language: en --- # The First Approved Brain–Computer Implant Is Now Helping Paralyzed Patients in China > Neuracle's NEO, the world's first regulator-cleared implantable brain–computer interface (脑机接口), moved from NMPA approval in March to a paying patient in July — a rare case of lab neurotech reaching a hospital ward. A man who lost the use of his hands in a car crash a decade ago lay in a Shanghai operating room this summer and, by thinking about it, closed a robotic glove. The implant in his skull is not a research prototype. It is a product a regulator cleared for sale — and he is among the first people on Earth to buy one. ## Key takeaways - China's NMPA cleared Neuracle Technology's NEO on 13 March 2026 — the world's first approved implantable brain–computer interface (脑机接口) medical device. - NEO is a coin-sized, wireless implant placed epidurally (on the brain's outer membrane, without penetrating tissue) that decodes motor signals to drive an assistive glove for grasping. - It is intended for patients aged 18–60 with tetraplegia caused by cervical spinal cord injury who cannot grasp. - The first commercial prescription was written on 13 July 2026 at Huashan Hospital, Fudan University — four months after approval. - China has an estimated 3.7 million people living with spinal cord injury and about 90,000 new cases a year, a large unmet need. ## From "first certificate" to "first prescription" The jump from approval to a paying patient took four months. NMPA's 13 March clearance made NEO the first implantable BCI cleared for marketing anywhere. On 13 July, Huashan Hospital affiliated with Fudan University wrote the first commercial prescription and performed the first commercial implant. Huashan had already completed an insurance pricing filing on 28 April, then moved through device admission, patient screening and preoperative assessment. The speed reflects a coordinated push: national regulators, Shanghai authorities and the hospital ran a continuous relay — production, hospital admission, patient screening and inclusion in a city-customized commercial insurance product, "Huiminbao" (沪惠保), all inside those four months. ## What the device actually does NEO is a coin-sized wireless implant laid on the epidural surface of the brain. Because it does not penetrate brain tissue, the approach trades some signal richness for lower surgical risk. It picks up signals from the motor cortex, decodes the patient's intent to move, and translates it into commands for a pneumatic glove, letting the user grasp objects, pick up items and drink. Patients can operate the system independently at home about one month after surgery. ## The patients behind the numbers So far the device has been used in 36 clinical procedures — four feasibility studies and 32 multi-centre Good Clinical Practice trials — and all participating patients showed some degree of improvement in grasping function, according to Xinhua's reporting on the developer. Mao Ying, president of Huashan Hospital, says the hospital has launched the world's first BCI clinical cohort study; based on assessments of 32 patients and a six-month neurological rehabilitation evaluation, the team has seen encouraging results, though patients need about six hours of rehabilitation training a day for more than a month before meaningful gains appear. The need is large. Estimates cited by Beijing News put the number of people in China living with spinal cord injury above 3.7 million, with roughly 90,000 new cases each year; about 70% were under 50 when injured. ## What still has to be proved NEO is narrow by design: upper-limb grasping for a specific injury group. Long-term implant stability, real-world durability and whether benefits hold outside trial centres are not yet established. Payment today rests on a single Shanghai insurance product; nationwide reimbursement is unresolved. Some institutions forecast China's BCI market reaching 5.58 billion yuan (≈US$818 million) by 2027 at about 20% annual growth, but that is a projection, not booked demand — and expansion to lower-limb recovery or language restoration remains aspirational. China is not alone in the race. Observers note competitors including Neuralink, Synchron and Precision Neuroscience, and the open question is whether Beijing's regulatory-first path converts a clearance into routine clinical care faster than its rivals. ## Why a regulator moved first China named brain–computer interface (脑机接口) a future industry in its 2026 Government Work Report and again in the 15th Five-Year Plan, signalling state backing well before the NEO clearance. That framing helps explain the four-month sprint from approval to prescription: when a technology is flagged as strategic, regulators, hospitals and insurers are authorised to move in concert rather than in sequence. The risk is that strategic priority can outrun the evidence on long-term safety. ## Honest limitations - NEO treats upper-limb grasping in a narrow patient group (cervical spinal cord injury, ages 18–60); it is not a general paralysis cure. - The 36 procedures are early clinical experience; long-term implant stability and real-world durability are not yet established. - Payment today rests on one Shanghai city-customized insurance product (沪惠保); nationwide reimbursement is unresolved. - Market-size forecasts to 2027 are analyst projections, not booked revenue, and depend on unproven scale-up. ## What readers can do now - For clinicians and patients' families: track Huashan Hospital's published cohort data and which hospitals gain approval to implant — adoption will be centre by centre. - For medtech watchers: watch implant longevity and the expansion beyond grasping; those determine whether this stays niche or scales. - For investors: separate the regulatory first from the reimbursement reality; the harder commercial question is payment, not approval. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-app-neo-bci-clinic Free to quote with attribution and a link to the original.